Over the last five years, there has been an increased emphasis on screening for aneuploidy, in part due to the ACOG endorsement of the concept of offering nuchal translucency (NT) and biochemical screening to all pregnant patients, and not just those of advanced maternal age (AMA).
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content